Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Generic Drug Makers Set For Bumper Harvest As Patents Expire

This article was originally published in PharmAsia News

Executive Summary

In 2007, some 35 drugs around the world lost their patent protection. For makers of generics, this presents an $82 billion opportunity. Industry experts see China's drug manufacturers having an edge thanks to their lower production and environmental protection costs, as well as strong ability to clone original products. At the same time, local enterprises face hurdles in the poorer quality of their generic drugs, low-level research and development, and inadequate understanding of the international market. The last shortcoming stems from the language gap in communication, the brief experience of the local industry in globalization, and limited exposure to overseas investment. (Click here for more)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts